Inclusion Criteria:

- Patients must have histologically confirmed diagnosis of prostate cancer

- Patients must have elected to undergo radical prostatectomy using an open,
laparoscopic or robotic approach

- Patients must be at least 18 years of age and able to provide written informed
consent.

- No history of radiotherapy, chemotherapy or hormone therapy within 6 months of
surgery

- Primary tumor must be amenable to surgical removal for curative intent

- Patients must have ECOG-performance status 0 or 1 (appendix II)

- Patients must have no history of rectal or anal disease.

- Patients must have adequate organ function as defined by the following criteria:

- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase
[SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase
[SGPT])≤2.5x local laboratory upper limit of normal (ULN), or AST and ALT ≤5x
ULN if liver function abnormalities are due to underlying malignancy

- Total serum bilirubin ≤1.5 x ULN

- Absolute neutrophil count(ANC)≥1,500/microL

- Platelets≥lOO,OOO/microL

- Hemoglobin≥9.0 g/dL

- Serum calcium≤10.2mg/dL (correct for low albumin if necessary; calcium + (normal
albumin - serum albumin)x 0.8)

- Patients must have serum creatinine<2 mg/dL or serum creatinine clearance
(CrCl)>40ml/min(CrCl= Wt(kg)x(140-age)*/72xCr. level,*female x 0.85)

Inclusion of minorities:

- Members of all races and ethnic groups are eligible for this trial. Women and
children are not eligible since prostate cancer is not diagnosed in these groups.